SAN DIEGO, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA‑ASI) is deepening its footprint in the Dutch innovation ecosystem, with new investments in six Netherlands-based technology companies through its Blue Magic Netherlands (BMN) venturing initiative.These new partnerships follow the latest BMN event in Eindhoven, a fast-paced, "shark tank"-style forum in which Dutch startups and scaleups pitched breakthrough technologies directly to GA‑ASI decision makers. The most recent edition drew more than 350 attendees from across the country's aerospace, defense, and high-tech communities.Building on the success of prior events, GA‑ASI has selected six Dutch companies for new investment and collaboration. GA-ASI also is increasing its investment in Emergent Swarm, first discovered at BMN 2024. Emergent Swarm is partnering with GA‑ASI to further mature its swarming autonomy detection capability."Blue Magic Netherlands is our window into the Dutch innovation ecosystem," said Brad Lunn, Managing Director, GA‑ASI. "We are not just scouting ideas. We are deploying capital, engineering resources, and access to platforms to help these companies scale. We're making these new investments because it is clear to us that the Netherlands is one of the most dynamic technology hubs in Europe."The six new GA‑ASI portfolio companies are:OPT/NET B.V. - GA-ASI, alongside its GA-Intelligence affiliate, will be working with OPT/NET to explore collaboration opportunities for a variety of AI-related missions, including drone swarm management and dark vessel detection.Vaeridion B.V. - GA-ASI will be working with Vaeridion to evaluate their advanced battery pack technology for use in current and future GA-ASI platforms.Touchwaves B.V. - GA-ASI will be evaluating Touchwaves' haptic technology for use in remotely piloted UAS environments to determine the potential benefits to long-duration missions and aircrew information overload.FDCL Defence B.V. - GA-ASI and GA-Intelligence will be working with Fiducial to explore the effectiveness of the company's technology toward massively scaled low-cost future platforms.Vydar Commercial B.V. - GA-ASI will evaluate Vydar's technology in a variety of relevant GPS-denied environments and GA-ASI and GA-EMS platforms.Emproof B.V. - GA-ASI will evaluate the effectiveness of Emproof's data protection technology for applicability to current and future GA-ASI platforms.GA‑ASI expects to announce additional investments from the 2025 BMN cohort in the coming months, as technical evaluations and co‑development discussions progress.About Blue Magic VenturesBlue Magic Ventures is GA‑ASI's corporate venturing initiative, designed to identify, invest in, and scale breakthrough technologies from startups and innovators around the world. Through capital investment, access to platforms, and deep technical collaboration, Blue Magic Ventures accelerates the path from concept to capability for dual‑use technologies.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HO CHI MINH / SEOUL, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - Global content-tech company TON Corporation (CEO Henry Kim) today announced that it will officially launch 'TonTV', its Telegram-native short-drama platform, worldwide in September 2026. TonTV lets the ~1 billion people who use Telegram each month instantly and freely watch short dramas with a single Telegram account — with no separate app install and no complicated sign-up.Short drama is one of entertainment's fastest-rising categoriesShort-form drama has moved to the center of global media consumption. Global in-app revenue for short dramas reached $2.98 billion in 2025, up 115% year over year, and in Q4 2025 short-form titles overtook long-form streaming apps in downloads for the first time (733M vs. 658M), according to Sensor Tower and Omdia. With short runtimes, high completion rates, and mobile-first immersion, the format is growing fastest among younger viewers. TonTV places dramas of around two minutes at the heart of this trend — short but intense chapters that build a "can't-stop-once-you-start" experience.The Telegram Mini App: tearing down the barrier to entryTonTV's core strength is that it runs atop Telegram, a massive global platform. Existing OTT services require a long entry sequence — app-store search → download → install → sign-up → enter payment details. TonTV removes it: open the Mini App inside Telegram → watch instantly, for free.The user reach that global OTT leaders such as Netflix and Disney+ built over years and at enormous cost is something TonTV can address from day one, across Telegram's ~1 billion monthly users. This dramatically lowers user-acquisition cost while driving early growth through natural word-of-mouth across Telegram's groups and channels.Three years of preparation, and "why we can win"TonTV did not appear overnight. Over the past three years, TON Corporation has focused on platform-technology development, global content partnerships, and a local-operations model in preparation for launch.CTO Tony cited the following reasons TonTV can be a market "game changer" rather than a late follower:Frictionless reach — among the first specialized short-drama platforms to reach Telegram's ~1 billion monthly users, free, in one clickFree entry — anyone can start at no cost, a strong advantage for early user acquisitionNetwork effects — discussion, sharing, and recommendation happen at the same moment as viewingViewer-participation rewards — enjoying content itself returns benefits and rewards, building loyaltySimultaneous global release — worldwide at once, with no region-by-region app-store approvalOn these strengths, TonTV aims to grow beyond short drama into real-time formats such as live streaming over time.A 'new stage' for producers, actors, and staff worldwideTonTV goes beyond a viewing platform to open opportunity for the global content industry. Producers can showcase work directly to a global audience; actors and staff can widen their stage across borders. For emerging teams and new actors who have struggled to get a chance at traditional broadcasters or large OTTs, TonTV offers an open stage judged on ability — creating jobs across planning, production, acting, and post-production."Global one platform, local content"TonTV places local subsidiaries in major markets — Korea, Japan, Vietnam, India, Indonesia, and the Philippines — planning and producing content suited to each region's culture on the ground. Combining a global platform's scale with local content's intimacy, TonTV aims to be a true global OTT where anyone can enjoy "stories from home." The local-subsidiary model expands content and markets quickly while keeping head-office cost low.A dual revenue model: "growth and profit together"TonTV operates a dual model: a free, ad-supported tier where all users watch at no cost, and a premium subscription for an ad-free experience. Advertiser acquisition and content production through local subsidiaries create a cycle in which ad and subscription revenue grow with the user base. Telegram's low acquisition cost and short-form's high completion rates support this model.Comment from TON Corporation CTO TonyCTO Tony said: "For the past three years we've focused everything on creating the easiest, most enjoyable way to watch drama. On Telegram — a playground of a billion people — TonTV sets a new standard for short drama anyone can enjoy free, with a single account."He added: "TonTV will create the best experience for viewers, a new stage for creators, and new jobs for the industry — and our ambition is to become the global leader in short-drama and live content."Future plansFrom its September 2026 launch, TonTV plans to rapidly expand its content lineup and service regions, broaden from short drama into real-time formats such as live streaming, and accelerate global expansion through its local subsidiaries.About TON CorporationTON Corporation is a global content-tech company headquartered in Ho Chi Minh, Vietnam. Through TonTV, its Telegram-native short-drama platform, it aims to deliver a new entertainment experience to users worldwide and open opportunity for global content creators.Media ContactBrand: TON CorporationContact: PR TeamWebsite: https://tontv.toncorp.ioTelegram: https://t.me/TontvOfficialChannel Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008"), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world's largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies.About CMS-D008CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection. It targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of INHBE-encoded Activin E protein, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. It demonstrates the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. Currently, the Phase I clinical trial of CMS-D008 in healthy subjects is progressing steadily. In the future, it may be developed for the treatment of abdominal obesity and related metabolic diseases.CMS-D008 has demonstrated encouraging preclinical data. The preclinical research results of CMS-D008 presented at the ADA Scientific Sessions showed that in obese animal models, CMS-D008 efficiently and sustainably suppressed INHBE expression, achieving significant weight loss and fat reduction while sparing muscle mass, with a favorable safety profile, indicating the potential for healthy weight loss. Details are as follows:Title: CMS-D008 specifically silences INHBE mRNA, delivering fat-selective weight loss in preclinical studyPresentation Number: 3079-LBPresentation format: PosterDate/Time: June 7, 2026 01:30 PM - 02:30 PM (Local Time)Location: Hall D-EResults:In a high-fat diet-induced model of humanized INHBE obese mouse (hINHBE DIO mouse), CMS-D008 significantly reduced hepatic INHBE mRNA expression and serum Activin E protein levels, leading to marked decreases in body weight, total body fat, and regional fat mass while preserving lean mass.In a model of obese cynomolgus macaque, CMS-D008 also significantly reduced hepatic INHBE mRNA expression and plasma Activin E protein levels, and effectively suppressed weight gain induced by a sustained high-fat diet.The inclusion of these findings at the ADA Scientific Sessions reflects the international academic community's interest in the scientific value and clinical potential of CMS-D008 in the field of obesity/metabolic treatment. CMS-D008 will synergize with CMS-D005, a self-developed, clinical-stage innovative drug (a GLP-1R/GCGR dual agonist), to deliver highly effective weight-loss benefits and long-term maintenance of results, providing patients with a more comprehensive and innovative treatment option.CMS is committed to in-house R&D as a core driver of its long-term growth and continues to advance innovation in cutting-edge therapeutic areas. Currently, 6 self-developed products with global rights, including CMS-D008, have entered the clinical stage, with over 20 additional self-developed projects steadily progressing in preclinical research. Looking ahead, the Group will continue to focus on unmet medical needs, efficiently advance product R&D and commercialization, and bring more comprehensive and innovative therapies to benefit broad patient population.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 8, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (“CORXEL”). Under the agreement, Everest has acquired the rights to develop, manufacture, and commercialize LNZ100 (1.44% aceclidine, U.S. brand name VIZZ) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region. Everest will pay an upfront payment and potential development milestone payments. As part of this agreement, Everest will be assigned and transferred the rights and obligations under the LENZ License Agreement entered into by CORXEL in April 2022 and certain related ancillary agreements. This transaction is expected to further expand the Company’s innovative product portfolio, strengthen its presence in ophthalmology, and enhance overall strategic synergies across its business.LNZ100 is a once-daily prescription eye drop indicated for the treatment of presbyopia. Its active ingredient, aceclidine, is a small molecule acetylcholine receptor agonist that causes pupil contraction, or miosis, creating a pinhole effect that improves near vision. Studies have shown that aceclidine's mechanism of action (MOA) is well positioned to create a pinhole pupil effect while avoiding the impairment of distance vision called myopic shift. Aceclidine's unique pupil selective MOA, in which miosis is decoupled from myopic shift, is expected to allow it to target a broad patient population.According to publicly available information, LNZ100 received approval in the United States in July 2025 and was commercially launched in October of the same year. In China, the New Drug Application (NDA) for LNZ100 was submitted in September 2025, with approval expected in the first quarter of 2027. The therapy has the potential to address a significant unmet medical need in China and position itself as a best-in-class, non-invasive treatment option for presbyopia.“The acquisition of LNZ100 represents an important step in advancing Everest’s strategic focus in ophthalmology. LNZ100 is a differentiated asset with meaningful clinical value and strong commercial potential in the treatment of presbyopia,” said Yifang Wu, Chairman of the Board of Everest Medicines. “As the presbyopia patient population continues to grow, significant unmet needs remain in non-invasive treatment options. We believe LNZ100 has the potential to offer patients a novel, non-invasive therapeutic option and to further broaden the landscape of innovative ophthalmic treatments. The product has already been approved in the United States and is currently under regulatory review in China. We will continue to advance its development and commercialization to make this therapy accessible to presbyopia patients.”Ms. Sandy Mou, Board Executive Director and Chief Executive Officer of CORXEL, said: “We are confident that Everest Medicines’ strong commercialization capabilities will accelerate LNZ100’s market access and bring this innovative treatment to more presbyopia patients in China. Following this transaction, CORXEL’s pipeline will be entirely focused on cardiometabolic therapies. The proceeds from the transaction will enable CORXEL to accelerate the global clinical development of its innovative cardiometabolic pipeline.”Presbyopia is a physiological phenomenon associated with aging that results in a progressively worsening ability to see nearby objects clearly. It is caused by the gradual hardening of the lens. This results in a decline of the eye’s adjustment function, and the inability to focus the image of nearby objects on the retina, leading to a decline in near vision. Studies have shown that the onset of presbyopia typically occurs around the age of 38, reaching a prevalence rate of nearly 100 percent at the age of 52 in China. Currently, the treatment options for presbyopia are very limited. Wearing glasses requires frequent removal and insertion, causing many inconveniences in work and life. Surgery, as an irreversible and invasive operation, has very limited acceptance. There are no approved drugs for the treatment of presbyopia in China and the medical need for non-invasive, safe, efficient and reversible treatments for presbyopia remains unsolved.The NDA acceptance of LNZ100 by the National Medical Products Administration (NMPA) of the People’s Republic of China is based on the data from China Phase 3 Trial. The study was a Phase 3, multicenter, randomized, double-blind, vehicle-controlled study, including a 4-week efficacy study followed by a 6-month extension safety study, designed to evaluate the efficacy and safety of LNZ100 (an aceclidine-based ophthalmic solution) in participants with presbyopia. The objectives were to assess the potential of LNZ100 to improve near vision among Chinese presbyopia patients and to evaluate the efficacy and safety profiles. The trial has enrolled 300 participants.The results showed that LNZ100 achieved the primary endpoint and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). Results also showed (all p